We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
...be rather helpful here. Don't really have lots of gaining shares in the p/f to sell in order to buy more GSK but if this SP continues to drift, might have to do just that. Incidentally, inserting a $B3 loss fund for Zantac payments seems harsh on GSK but then everyone seems to have it in for them these days!
It is Pfizer who are making the maternal RSV vaccine, not GSK.
https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention-0
I am getting a video picture in picture about one tenth of screen every time I open a share on my saved shares list.
Its not an add, its actually vids about companies. anyone know how to stop this please. W10. Brave browser. Apart from this add free.
I was listening to the latest TWiV [This Week in Virology]... They mentioned that GSK have got 2/3s of the market in the US, that the CDC is now recommending the vaccines to over 60s & that they want pregnant women in their last trimester to be vaccinated to pass on the antibodies to newborns. Sales of the RSV vaccine might surpass market expectations.
https://www.youtube.com/watch?v=hKfU4g1MKZM
Well documented to be replaced by far better and less regular treatments. The only concern still hanging over GSK is the Zantac lawsuit
HIV patent expires soon for starters
Solomon - Arexvy was a big feature in yesterday's post result webcast and it is what virtually all the analysts wanted to talk about. It was only launched in Q3 and achieved sales of £709m "benefitting from strong demand and initial channel inventory build. It has approval in US, EU, Canada and Japan but it is far too early to say if it is going to be a "winner" or not. They need more efficacy studies; they undertook one on 50 - 59 year olds which showed "positive data" and are working on others. They did say they were beating Pfizer on RSV products but it really is too soon to judge but you are correct in saying there is some inventory build and there will be this time next year because of the seasonal bias in it's use.
The share price has been awful since yesterday's profit upgrade but looking at the trades it doesn't look like chunky institutional business. Who knows how the Zantac litigation will turn out - here is what the company has to say about it https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation/ I'm sticking with my shares and a "buy" status but like everyone I get some wrong!
Ok. It sounds like the company are being more guarded about Arexvy growth and just tempering expectations for ‘24. It doesn’t take much to know this when everyone is so utterly bored of it. Hard to believe I once sold these shares at £20 in the late 90’s. Wish I’d just left them alone ever since. I see a few comments here about a potential bid for them. It feels unlikely given their perceived strategic importance to the politicians, but I know institutions would bite the hand off anyone bidding much above say £18
Just came on here to try and find out what’s happened. It’s weird isn’t it? There must be some big downgrade around. I’ll dig around and come back.
I guess that its down to the usual culprits. Institutional selling, disappointment in not meeting the "whisper" number, and company debt. Leaving out the ongoing Zantec litigation.
I'd like to see GSK put in a £15bn bid for Avacta and become the gold standard in oncology for breast cancer, soft tissue sarcoma, liver and and pancreatic cancer. Would be nice to keep a British pharma giant instead of being sold off on the cheap
Solomon - I think you are right about the stock building - I read it in yesterdays report. However as with all new things initial uptake likely to be lower, with peak revenues further down the road as the treatment becomes increasingly well known.
As for the 5% fall in SP - IMO just MM shaking the tree to see what falls. I'm staying put, but not committing any further funds at this point.
New RSV treatment might not be a blockbuster- initial sales represent an inventory build - not saying this is the reason for the drop which is weird, agreed
At this price, I reckon one or two foreign big names will be looking at a take out. Below £13.95 and with our catalogue of potential new drugs, a cheap and cheeky bid is now a real likelihood.
I really am struggling to understand this 4.5-5% drop since the excellent Q3 results were communicated yesterday. When I first saw the results I fully expected us to be at around the £15.5 mark this time today.
I do wonder why i can hold of this stock....yes divi's are nice but no SP growth whatsoever. It's so frustrating !
Should have cashed in ages ago and invested elsewhere. Hey ho !
Finished -2.4% on the day it announced excellent results.
What the market does not understand is that the Zantac litigation is like a pimple to thiscompany and because of limitation of actions, it is soon going to be impossible for there to be ANY new attempted actions. GSK's legal team have all the existing ones in hand and the payouts, although never in the public domain. amount to no more than a minor irritation in the Annual figures, gradually reducing to nil over the next few years.
And those belly-aching about no increase being announced in the quarterly figures, there is nothing to prevent the Board from either announcing that at year end or even announcing a Special Dividend,
Lets see what the so-called Pundits have to say tomorrow.
Hugely successful results and the shares go down. Yoof - buy. Us Oldies hold on. This is a really good company.
What Debt mountain? - that belongs to Haleon now
It amazes me that after years of being slated for having too generous a dividend GSK is now told the dividend must now be increased. Seriously GSK cannot seem to please anyone. AZ remains the darling despite being totally over valued and dependent on a charismatic leader that won't be there much longer.
1405p to buy? What the hell was that all about?
Investors expecting a raised dividend?
I added to my holding as the drip drip effect of all the positive news of late will surely have an effect in the long term.
Debt mountain and Zantac remain negatives but can be overcome in the medium term.
One for the SIPP
Well it turned out to be interesting. Management did, of course, cover the upgrade with pride but most of the presentation was spend on the progress of recent drug launches and the pipeline. All the analysts questions were about about this some of it, I admit, was above my head but the flavour was positive. They were trying to get a handle on how much to upgrade their forecasts for YE 2024. One that stands out is "Arexvy" (It was approved by the US FDA on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 and older.)
We have clear profit guidance for this year although further strengthening of sterling against US dollar compared with last year would be a negative. Cash generation looks OK and margins are up. The CEO was absolutely clear there is "sustained momentum" and referred to 2026. If the board watch the share price (and they do) they will be gutted to see a fall on the day they make an upgrade for the year 2024. But this is a market and when there are more sellers than buyers we know what happens. I expect the forecasts for the next two years to be raised and its not as though it is a highly rated share today so I have given it a "weak buy" rating. I'm not too concerned about the dividend not rising, it yields enough already!